Article Text

other Versions

PDF
Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups
  1. Joyce M Leo1,2,
  2. Steve E Kalloger2,3,
  3. Renata D Peixoto4,
  4. Nadia S Gale5,
  5. Douglas L Webber1,2,3,
  6. David A Owen1,2,3,
  7. Daniel Renouf2,3,4,
  8. David F Schaeffer1,2,3
  1. 1Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada
  2. 2The University of British Columbia, Vancouver, British Columbia, Canada
  3. 3Pancreas Centre BC, Vancouver, British Columbia, Canada
  4. 4Division of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
  5. 5Anatomical Pathology, BC Cancer Agency, Vancouver, British Columbia, Canada
  1. Correspondence to Dr David F Schaeffer, Division of Anatomic Pathology, Vancouver General Hospital, 910 W. 10th Avenue, Vancouver, British Columbia, Canada V5Z 1M9; david.schaeffer{at}vch.ca

Abstract

Background Ampullary carcinomata (AC) can be separated into intestinal (IT) or pancreatobiliary (PB) subtypes. Although morphological, immunohistochemical and molecular differentiation of IT and PB have been well documented; the prognostic significance of histological subtype and whether patients with either subtype benefit from differential chemotherapeutic regimens remains unclear.

Methods As part of a larger cohort study, patients who underwent resection for AC or pancreatic ductal adenocarcinoma (PDAC) were retrospectively identified. Clinicopathological covariates and outcome were obtained and MUC1, MUC2, CDX2 and CK20 were assessed with immunohistochemistry.

Results Of 99 ACs, the resultant immunophenotypes indicated 48% and 22% were IT and PB, respectively. Thirty (30%) cases were quadruple negative (QN). Within the PDAC cohort (N=257), the most prevalent immunophenotype was QN (53%). Subsequently, all QN ACs were classified as PB immunohistochemically yielding 47.5% and 52.5% classified as IT and PB, respectively. Involved regional lymph nodes and elevated T-stage were significantly associated with PB compared with IT AC (p=0.0032 and 0.0396, respectively). Progression-free survival revealed inferior survival for PB versus IT AC (p=0.0156).

Conclusions AC can be classified into prognostic groups with unique clinicopathological characteristics using immunohistochemistry. Immunophenotypical similarity of PB and PDAC suggests that treatment regimens similar to those used in PDAC should be explored.

  • HISTOPATHOLOGY
  • CANCER
  • PANCREAS
  • CHEMOTHERAPY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.